SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions

被引:9
作者
Bennett, Rory [1 ]
Thompson, Ella [1 ,2 ]
Tam, Constantine [3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Parkville, Vic, Australia
[3] Alfred Hlth, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
关键词
Venetoclax; Targeted therapy; Resistance; Oligoclonal; Selection pressure; IBRUTINIB PLUS VENETOCLAX; KAPPA-B ACTIVATION; PHASE-I; CLL; EXPRESSION; ABT-199; FAMILY; PHOSPHORYLATION; PROGRESSION; APOPTOSIS;
D O I
10.1016/j.clml.2022.07.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukaemia (CLL) constitutively overexpresses B-cell lymphoma 2 (BCL2) with consequent dysregulation of intrinsic apoptosis leading to abnormal cellular survival. Therapeutic use of BCL2 inhibitors (BCL2i, eg, venetoclax) in CLL, as both continuous monotherapy or in fixed duration combination, has translated scientific rationale into clinical benefit with significant rates of complete responses, including those without detectable minimal residual disease. Unlike with chemotherapy, response rates to venetoclax do not appear to be influenced by pre-existing chromosomal abnormalities or somatic mutations present, although the duration of response observed remains shorter for those with traditional higher risk genetic aberrations. This review seeks to describe both the disease factors that influence primary venetoclax sensitivity/resistance and those resistance mechanisms that may be acquired secondary to BCL2i therapy in CLL. Baseline venetoclax-sensitivity or -resistance is influenced by the expression of BCL2 relative to other BCL2 family member proteins, microenvironmental factors including nodal T-cell stimulation, and tumoral heterogeneity. With selection pressure applied by continuous venetoclax exposure, secondary resistance mechanisms develop in oligoclonal fashion. Those mechanisms described include acquisition of BCL2 variants, dynamic aberrations of alternative BCL2 family proteins, and mutations affecting both BAX and other BH3 proteins. In view of the resistance described, this review also proposes future applications of BCL2i therapy in CLL and potential means by which BCL2i-resistance may be abrogated.
引用
收藏
页码:795 / 804
页数:10
相关论文
共 77 条
[1]   Targeting the Bcl-2 Family in B Cell Lymphoma [J].
Adams, Clare M. ;
Clark-Garvey, Sean ;
Porcu, Pierluigi ;
Eischen, Christine M. .
FRONTIERS IN ONCOLOGY, 2019, 8
[2]   Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma [J].
Agarwal, Rishu ;
Chan, Yih-Chih ;
Tam, Constantine S. ;
Hunter, Tane ;
Vassiliadis, Dane ;
Teh, Charis E. ;
Thijssen, Rachel ;
Yeh, Paul ;
Wong, Stephen Q. ;
Ftouni, Sarah ;
Lam, Enid Y. N. ;
Anderson, Mary Ann ;
Pott, Christiane ;
Gilan, Omer ;
Bell, Charles C. ;
Knezevic, Kathy ;
Blombery, Piers ;
Rayeroux, Kathleen ;
Zordan, Adrian ;
Li, Jason ;
Huang, David C. S. ;
Wall, Meaghan ;
Seymour, John F. ;
Gray, Daniel H. D. ;
Roberts, Andrew W. ;
Dawson, Mark A. ;
Dawson, Sarah-Jane .
NATURE MEDICINE, 2019, 25 (01) :119-+
[3]   An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737 [J].
Al-Harbi, Sayer ;
Hill, Brian T. ;
Mazumder, Suparna ;
Singh, Kamini ;
DeVecchio, Jennifer ;
Choudhary, Gaurav ;
Rybicki, Lisa A. ;
Kalaycio, Matt ;
Maciejewski, Jaroslaw P. ;
Houghton, Janet A. ;
Almasan, Alexandru .
BLOOD, 2011, 118 (13) :3579-3590
[4]  
Al-Sawaf O, 2020, LANCET ONCOL, V21, P1188, DOI 10.1016/S1470-2045(20)30443-5
[5]   Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax [J].
Anderson, Mary Ann ;
Tam, Constantine ;
Lew, Thomas E. ;
Juneja, Surender ;
Juneja, Manu ;
Westerman, David ;
Wall, Meaghan ;
Lade, Stephen ;
Gorelik, Alexandra ;
Huang, David C. S. ;
Seymour, John F. ;
Roberts, Andrew W. .
BLOOD, 2017, 129 (25) :3362-3370
[6]   Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations [J].
Birkinshaw, Richard W. ;
Gong, Jia-nan ;
Luo, Cindy S. ;
Lio, Daisy ;
White, Christine A. ;
Anderson, Mary Ann ;
Blombery, Piers ;
Lessene, Guillaume ;
Majewski, Ian J. ;
Thijssen, Rachel ;
Roberts, Andrew W. ;
Huang, David C. S. ;
Colman, Peter M. ;
Czabotar, Peter E. .
NATURE COMMUNICATIONS, 2019, 10 (1)
[7]   Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL [J].
Blombery, Piers ;
Lew, Thomas E. ;
Dengler, Michael A. ;
Thompson, Ella R. ;
Lin, Victor S. ;
Chen, Xiangting ;
Nguyen, Tamia ;
Panigrahi, Ashish ;
Handunnetti, Sasanka M. ;
Carney, Dennis A. ;
Westerman, David A. ;
Tam, Constantine S. ;
Adams, Jerry M. ;
Wei, Andrew H. ;
Huang, David C. S. ;
Seymour, John F. ;
Roberts, Andrew W. ;
Anderson, Mary Ann .
BLOOD, 2022, 139 (08) :1198-1207
[8]   BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia [J].
Blombery, Piers ;
Thompson, Ella R. ;
Chen, Xiangting ;
Nguyen, Tamia ;
Anderson, Mary Ann ;
Westerman, David Alan ;
Seymour, John F. ;
Tam, Constantine S. ;
Dengler, Michael A. ;
Huang, David C. S. ;
Wei, Andrew ;
Roberts, Andrew W. .
BLOOD, 2020, 136
[9]   Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax [J].
Blombery, Piers ;
Thompson, Ella R. ;
Tamia Nguyen ;
Birkinshaw, Richard W. ;
Gong, Jia-Nan ;
Chen, Xiangting ;
McBean, Michelle ;
Thijssen, Rachel ;
Conway, Thomas ;
Anderson, Mary Ann ;
Seymour, John F. ;
Westerman, David A. ;
Czabotar, Peter E. ;
Huang, David C. S. ;
Roberts, Andrew W. .
BLOOD, 2020, 135 (10) :773-+
[10]   Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia [J].
Blombery, Piers ;
Anderson, Mary Ann ;
Gong, Jia-nan ;
Thijssen, Rachel ;
Birkinshaw, Richard W. ;
Thompson, Ella R. ;
Teh, Charis E. ;
Nguyen, Tamia ;
Xu, Zhen ;
Flensburg, Christoffer ;
Lew, Thomas E. ;
Majewski, Ian J. ;
Gray, Daniel H. D. ;
Westerman, David A. ;
Tam, Constantine S. ;
Seymour, John F. ;
Czabotar, Peter E. ;
Huang, David C. S. ;
Roberts, Andrew W. .
CANCER DISCOVERY, 2019, 9 (03) :342-353